---
title: "MicroPort MedBot Sets 2026 AGM With New Capital Mandates on the Table"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286426445.md"
description: "Shanghai MicroPort MedBot (Group) Co., Ltd. has scheduled its annual general meeting for June 5, 2026, in Shanghai. Shareholders will review the 2025 annual report and vote on a proposed 20% share issuance and a 10% share buyback mandate. These measures aim to enhance capital structure and support funding needs. The company, listed under HK:2252, focuses on advanced surgical robotics and has a current market cap of HK$28.73B. Analysts rate the stock as a Buy with a price target of HK$45.00."
datetime: "2026-05-14T13:11:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286426445.md)
  - [en](https://longbridge.com/en/news/286426445.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286426445.md)
---

# MicroPort MedBot Sets 2026 AGM With New Capital Mandates on the Table

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ).

Shanghai MicroPort MedBot (Group) Co., Ltd. has called its annual general meeting for 5 June 2026 in Shanghai, where shareholders will review the 2025 annual report, supervisory committee report and proposed profit distribution plan, as well as vote on the re-appointment of KPMG entities as domestic and overseas auditors. The meeting will also ask investors to approve a 20% share issuance mandate and a 10% share buyback mandate, giving the board significant flexibility to adjust the company’s capital structure, support funding needs and manage shareholder returns in response to market conditions.

If approved, the new share issuance authority would allow directors to tap equity markets more efficiently for growth or strategic initiatives, while the buyback mandate could be used to signal confidence in the company’s valuation and optimize balance-sheet structure. These governance and capital-management proposals are standard for Hong Kong-listed issuers but are nonetheless important for existing and prospective investors, as they shape how management can respond to future financing, investment and market opportunities.

The most recent analyst rating on (HK:2252) stock is a Buy with a HK$45.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

**More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H**

Shanghai MicroPort MedBot (Group) Co., Ltd. is a China-based medical technology company focused on developing and commercializing advanced surgical robotics and related medical devices. Listed in Hong Kong under stock code 2252, it operates in the high-growth medtech segment targeting both domestic and international healthcare markets.

**Average Trading Volume:** 6,168,906

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$28.73B

### Related Stocks

- [02252.HK](https://longbridge.com/en/quote/02252.HK.md)

## Related News & Research

- [MicroPort MedBot Proposes New Share Scheme to Replace Existing Incentive Plans](https://longbridge.com/en/news/286423581.md)
- [The Trading Awards: Voting is open until 19 May](https://longbridge.com/en/news/286793607.md)
- [Figure AI had one of its robots race a human to sort packages. It lost.](https://longbridge.com/en/news/286883540.md)
- [Edianyun announces annual general meeting](https://longbridge.com/en/news/287032899.md)
- [Frequentis shareholders vote on proposal to authorize up to 10% share buyback](https://longbridge.com/en/news/287022917.md)